In:
Cancer, Wiley, Vol. 123, No. 24 ( 2017-12-15), p. 4914-4923
Kurzfassung:
To identify promising novel agents for the treatment of patients with recurrent neuroblastoma, appropriate phase 2 trial designs should be informed by historical benchmarks for progression‐free survival, time to disease progression, and overall survival, and stratified by factors prognostic of outcome after disease recurrence. The outcome for patients with recurrent neuroblastoma remains dismal. The results of this large, inclusive, representative meta‐analysis of 383 patients with recurrent neuroblastoma from 35 phase 1 trials and 2 Children's Oncology Group trials of modern‐era therapy (2002‐2014) provide context for designing new studies.
Materialart:
Online-Ressource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v123.24
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2017
ZDB Id:
1479932-7
ZDB Id:
2599218-1
ZDB Id:
2594979-2
ZDB Id:
1429-1